FDA's DDMAC Provides Insight on Pharmaceutical Companies and Web 2.0 in Eye on FDA Podcast

Share Article

Eye on FDA, a specialty blog written by Mark Senak, Senior Vice President at Fleishman-Hillard in Washington, D.C., posts an interview with the new official at FDA's DDMAC in charge of Web 2.0 policy development providing insight into FDA's point of view about the use of New and Social Media in Web 2.0 by the pharmaceutical industry.

Today Eye on FDA, a specialty blog written by Mark Senak, Senior Vice President at Fleishman-Hillard in Washington, D.C., posted a podcast recorded at the FDA on March 11, 2009 that interviews Dr. Jean Ah Kang, the official at FDA's DDMAC who is in charge of policy development with respect to pharmaceutical company use of new and social media in Web 2.0 marketing and communications efforts.

The pharmaceutical industry has been slow to embrace Web 2.0 because of regulatory concerns that reaching out to patients using social and digital media might provoke action by the FDA's Division of Drug Marketing Advertising and Communications (DDMAC). To date, the FDA has relied on traditional regulatory principles in evaluating pharmaceutical company use of Web 2.0 but has provided little insight on the agency's thinking of the many evolving communications in digital and social media.

Today, Eye on FDA posted Mark Senak's podcast interview with Dr. Jean Ah Kang, Special Assistant to DDMAC head Tom Abrams, who is in charge of the development of Web 2.0 policy for the FDA. They discussed whether or not the current regulatory environment prohibits pharmaceutical involvement in Web 2.0; what kind of considerations pharmaceutical companies need to consider; FDA's thoughts on specific situations involving social and digital media use; and how companies considering digital strategies should approach the FDA for input. It may well be the most complete public statement by the FDA on the topic to date.

Makr Senak's Eye on FDA

'Eye on FDA' has a diverse 'readership', including national media, government officials, patient groups, law firms, stock analysts and pharmaceutical companies themselves.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brian Batchelder
Visit website